MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Levodopa impairs learning in healthy young adults: Implications for Parkinson’s disease

    P.A. MacDonald, A. Vo, K.N. Seergobin (London, ON, Canada)

  • Levodopa induced dyskinesia and nicotinergic α4β2 acetylcholin receptor density: A multi-tracer imaging study

    J. Brumberg, S. Küsters, G. Marotta, M.M. Reich, F. Steigerwald, A. Buck, J. Volkmann, S. Samnick, I.U. Isaias (Würzburg, Germany)

  • Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

    W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)

  • Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

    K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)

  • Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

    E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

  • Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

    M. Senek, D. Nyholm (Uppsala, Sweden)

  • Levodopa-responsive hereditary spastic paraplegia, SPG35, due to FA2H mutations in siblings

    Y. Xing, J.R. Friedman (La Jolla, CA, USA)

  • Levodopa, placebo and rotigotine change biomarker levels for oxidative stress

    S. Muhlack, M. Kinkel, L. Herrmann, L. Tönges, T. Müller (Bochum, Germany)

  • Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study

    P. Havránková, J. Klempír, M. Fialová, A. Rezková, J. Petrtýl, V. Capek, E. Ruzicka, J. Roth, R. Jech (Praha, Czech Republic)

  • Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

    S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)

  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 207
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley